Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

136.01 +0.80 (+0.59%)
Streaming Delayed Price Updated: 12:55 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 101,356
Open 135.67
Bid (Size) 135.76 (4)
Ask (Size) 136.30 (1)
Prev. Close 135.21
Today's Range 134.55 - 136.38
52wk Range 85.28 - 161.00
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend. 
Via Benzinga

Performance

YTD
+6.65%
+6.65%
1 Month
+6.38%
+6.38%
3 Month
-4.29%
-4.29%
6 Month
+1.38%
+1.38%
1 Year
+57.24%
+57.24%

More News

Read More
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
Via Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
Via Benzinga
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Via Benzinga
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
Via InvestorPlace
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Via Benzinga
Exposures Product Safety
Masters In Trading - Saturday, May 11
Via Talk Markets
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
Via Benzinga
How Is The Market Feeling About Ascendis Pharma?
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Via Talk Markets
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
Via Benzinga
Earnings Scheduled For February 7, 2024
Via Benzinga
Ascendis Pharma's Earnings: A Preview
Via Benzinga
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.